A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
← catalyst calendarNCT06850038 · readout in 1,564 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
30estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-22 | actual | When the study began enrolling |
| Primary completion | 2030-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alagille Syndrome
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants with Alagille syndrome (ALGS) who are treated with odevixibat and undergo biliary diversion surgery or liver transplantation.
measured From first dose to end of study (approximately 5 years data collection)
Surgical biliary diversion-free survival
measured From first dose to end of study (approximately 5 years data collection)
Liver transplant-free survival
measured From first dose to end of study (approximately 5 years data collection)
Overall survival
measured From first dose to end of study (approximately 5 years data collection)
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed